PARSIPPANY, NJ–(Marketwired – Dec 23, 2013) – The Medicines Company (NASDAQ: MDCO) today announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational intravenous antiplatelet agent, cangrelor.

Source: http://www.marketwired.com/mw/release.do?id=1864874&sourceType=3

This entry was posted on Monday, December 23rd, 2013 at 2:00 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.